Editas Medicine, Inc. Common Stock (EDIT) is a publicly traded Healthcare sector company. As of May 20, 2026, EDIT trades at $2.61 with a market cap of $247.70M and a P/E ratio of -2.19. EDIT moved +6.10% today. Year to date, EDIT is +20.00%; over the trailing twelve months it is +65.10%. Its 52-week range spans $0.91 to $4.54. Analyst consensus is buy with an average price target of $6.60. Rallies surfaces EDIT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Editas Medicine’s EDIT-401 Cuts LDL-C by ≥90% for Six Months in Primates: Editas Medicine’s preclinical data shows a single 1.5–3.0 mg/kg dose of EDIT-401 in non-human primates produced ≥90% mean LDL-C reduction durable through six months with a promising safety profile and no adverse observations at therapeutically relevant doses. EDIT-401 achieved ≥6-fold hepatic LDLR protein increase with only 10–40% functional editing, while mouse studies indicate dose adjustments may not be needed for heterozygous familial hypercholesterolemia patients.
| Metric | Value |
|---|---|
| Price | $2.61 |
| Market Cap | $247.70M |
| P/E Ratio | -2.19 |
| EPS | $-1.17 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.54 |
| 52-Week Low | $0.91 |
| Volume | 1.21M |
| Avg Volume | 0 |
| Revenue (TTM) | $38.69M |
| Net Income | $-108.95M |
| Gross Margin | 0.00% |
10 analysts cover EDIT: 0 strong buy, 5 buy, 3 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.60.